Satralizumab (Enspryng) maintained reductions in eye bulging for roughly 85% of responders with thyroid eye disease through 48 weeks, according to pooled phase 3 data presented this week at the American Thyroid Association 2026 Meeting in a combined analysis of the SatraGO-1 and SatraGO-2 trials.
Madhura Tamhankar, MD, of the University of Pennsylvania in Philadelphia, presented the findings, which combine results from two earlier phase 3 trials to assess how patients with active, moderate-to-severe thyroid eye disease responded to the drug over 48 weeks. The week 24 results appeared in Ophthalmology in September, and the FDA approved satralizumab for thyroid eye disease in October — making it the first interleukin-6 (IL-6) receptor inhibitor approved for the condition.
Why it matters: thyroid eye disease, an autoimmune inflammation of the tissues behind the eye driven by the same immune dysfunction as Graves’ disease, can cause bulging eyes (proptosis), double vision, and in severe cases compression of the optic nerve. Until recently, treatment options were limited to intravenous steroids, the off-label IL-6 inhibitor tocilizumab, the insulin-like growth factor inhibitor teprotumumab, and surgery.
Eye bulging improvements sustained through week 48
- Most patients whose eye bulging improved in the first 24 weeks of satralizumab treatment kept that improvement through 48 weeks — whether they stayed on the drug or switched to placebo.
- More than half of patients who did not respond early still saw their eye bulging improve by week 48.
- The drug is given as an injection under the skin, which patients could potentially self-administer — but it costs about $18,000 per syringe without insurance.
How the SatraGO trials worked
In SatraGO-1 and SatraGO-2, 258 patients with active, moderate-to-severe thyroid eye disease were randomly assigned to receive satralizumab or a placebo subcutaneously during the first 24 weeks. Researchers then assessed whether patients had experienced a reduction in eye bulging and inflammation.
During the following 24-week period, the 47 patients who had initially responded to satralizumab were randomized to either remain on the medication or be switched to placebo, according to Tamhankar, while non-responders kept taking the drug. Patients who had initially received placebo but did not respond were switched to satralizumab.
At week 48, nearly 85% of initial responders maintained their proptosis response, regardless of whether they received satralizumab or placebo after week 24 — suggesting the treatment effect was sustained through the end of the study, Tamhankar said. Among the placebo group, the proptosis response was maintained in 83.3% and the overall response in 82.6%.
Among patients who did not initially respond, more than half — 24 of 45 — had improvements in bulging after 48 weeks, according to the researchers.
| Outcome at week 48 | Result |
|---|---|
| Initial responders maintaining proptosis response | Nearly 85% |
| Placebo responders maintaining proptosis response | 83.3% |
| Placebo responders maintaining overall response | 82.6% |
| Initial non-responders with improved bulging | 24 of 45 |
A convenient option — with caveats
Satralizumab had fewer adverse effects than other treatments for thyroid eye disease, including the off-label IL-6 inhibitor tocilizumab, Tamhankar said. Because the drug has been used for years to treat neuromyelitis optica spectrum disorder to help reduce inflammation, a wealth of safety data are available, she added.
“It’s an extremely attractive option in certain patients who may have a lot of inflammation but may not have as much proptosis to begin with,” she said.
She also noted satralizumab was less effective at reducing proptosis than insulin-like growth factor inhibitors. “But does it compare better with regards to adverse effects? Yes,” she said.
Not everyone is convinced. Raymond Douglas, MD, an oculoplastic surgeon at Cedars-Sinai in Los Angeles, called the results “lackluster.” He pointed to the high placebo response in one of the trials, which he said was “characteristic of drugs with marginal benefit,” and to the fact that SatraGO-1 did not meet statistical significance for improvement at week 24.
According to Tamhankar, the investigators could not explain why a single trial failed to reach statistical significance, though she suggested that the “ambiguity of measuring clinical activity score, which is quite subjective” and “inexperience of investigators in different countries” might have contributed.
The cost question
Douglas, who was not involved in the new research, said that other medications are available at one twentieth of the cost, such as tocilizumab. “Satralizumab has a very modest biologic effect but will carry a very hefty price tag,” he said. Without insurance, the injections cost around $18,000 per syringe.
He conceded, however, that because satralizumab is administered subcutaneously, patients could potentially treat themselves. “Convenience really matters in those circumstances and in those areas where care may be very difficult to obtain or the doctor may not be nearby,” Tamhankar said.
For patients in the United States, the FDA approval in October means satralizumab can now be prescribed specifically for thyroid eye disease; coverage decisions will rest with individual insurers. Patients in the UK and Europe have no equivalent approval yet from the EMA or NHS regulators, and access there would depend on future submissions by Genentech, which markets Enspryng and provided funding for the study.
Disclosure note: Douglas is a consultant for Amgen and Viridian, which manufacture treatments for thyroid eye disease. Tamhankar is a consultant and advisor for Genentech, which markets Enspryng and provided funding for the study.
Infection and liver risks require doctor consultation
Satralizumab works by blocking interleukin-6, a chemical messenger that drives inflammation. By dampening that pathway, it can lower the body’s defenses against certain infections, so patients with active or chronic infections should discuss the risks with their treating physician before starting therapy. Anyone with a history of liver abnormalities should also be monitored, as is standard with IL-6 inhibitors.
Patients with thyroid eye disease should seek prompt medical attention for worsening eye pain, double vision, color vision changes, or reduced visual acuity — these can signal optic nerve compression, which requires urgent treatment regardless of which drug a patient is on. Treatment decisions should be made with an ophthalmologist or endocrinologist familiar with the condition; this article is reporting on clinical research, not medical advice for any individual.
The meeting’s host, the American Thyroid Association, traces its roots to December 9, 1923, when the Illinois Clinical Club met in Bloomington and founded “The American Association for the Study of Goiter.” The first official meeting followed in January 1924 at St. Joseph’s Hospital, and the organization took its current name in 1961. It marked its centennial in 2023 and now counts more than 1,700 medical specialists among its members worldwide.
The open question now is where satralizumab fits in the treatment sequence — a question the divergent verdicts of its own presenters leave unresolved. “Satralizumab has a very modest biologic effect but will carry a very hefty price tag,” Douglas said.
References
- Tamhankar M, et al. Combined SatraGO-1 and SatraGO-2 phase 3 analysis, presented at the American Thyroid Association 2026 Meeting.
- Week 24 results from the SatraGO trials, published in Ophthalmology, September 2026.
- Medscape Medical News, coverage of the ATA 2026 Meeting, reporting by Avery Orrall.
- U.S. Food and Drug Administration, October 2026 approval of satralizumab for thyroid eye disease.